PaquissiFC. The role of inflammation in cardiovascular diseases: the predictive value of neutrophil-lymphocyte ratio as a marker in peripheral arterial disease. Ther Clin Risk Manag. 2016;12:851–60.
2.
ChangZZhengJLiuZGuoQ. The relationship between the neutrophil-lymphocyte ratio and in-stent restenosis in patients with femoropopliteal chronic total occlusions. Angiology. 2018;69:177–82.
3.
BaltaSDemirkolSKucukUCelikTOzturkCIyisoyA. The relationship between neutrophil-lymphocyte ratio and coronary collateral circulation. Perfusion. 2014;29:367–8.
4.
HoenderdosKCondliffeA. The neutrophil in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2013;48:531–9.
5.
BaltaSOzturkCKurtogluE. The neutrophil-lymphocyte ratio is not enough to describe inflammatory condition. Eur Arch Otorhinolaryngol. 2014;271:1839–40.
6.
WeltFGRogersC. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22:1769–76.
7.
CelikIEYarliogluesMKurtulA. Preprocedural albumin levels and risk of in-stent restenosis after coronary stenting with bare-metal stent. Angiology. 2016;67:478–83.
8.
YilmazSSenFAkbogaMK. The relationship between resting heart rate and SYNTAX score in patients with stable coronary artery disease. Angiology. 2017;68:168–73.
9.
Van BelleEKetelersRBautersC. Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: a key determinant of survival in diabetics after coronary balloon angioplasty. Circulation. 2001;103:1218–24.
10.
KamiokaNSogaYKuramitsuS. Clinical outcomes of balloon angioplasty alone versus nitinol stent implantation in patients with small femoropopliteal artery disease: observations from the Retrospective Multicenter Analysis for Femoropopliteal Stenting (REAL-FP). Catheter Cardiovasc Interv. 2017;90:790–7.
